A prospective, single-center, single-arm, single-blind pilot study is currently investigating the efficacy of tofacitinib in patients with refractory MG (ClinicalTrials.gov, NCT04431895 [99]); Ruxolitinib, a selective JAK1 and JAK2 inhibitor, induced clinical remission in a MuSK-positive MG patient who had undergone treatment for myelofibrosis [100]. Here, JAK2 is linked to myasthenia gravis.